AT
REGN icon

Arvest Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Arvest Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-296
Closed -$220K – 165
2023
Q2 		$220K Buy
296
+10
+3% +$7.71K 0.01% 161
2023
Q1 		$235K Sell
286
-4
-1% -$3.02K 0.01% 143
2022
Q4 		$209K Buy
+290
New +$214K 0.01% 167

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arvest Trust's REGN Position: Q3 2023 in Review

Arvest Trust sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 296 shares — an estimated $220K sold.

Arvest Trust first reported a position in REGN in Q4 2022 and held it in 3 quarters. The position peaked at $235K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Arvest Trust reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Arvest Trust sold 296 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $220K.
  • Arvest Trust first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Arvest Trust's Regeneron Pharmaceuticals position peaked at $235K in Q1 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Arvest Trust's 13F filing for Q3 2023, filed 14 Nov 2023.